Does the media prefer BLTE or XERS?

In the previous week, Xeris Biopharma had 14 more articles in the media than Belite Bio. MarketBeat recorded 19 mentions for Xeris Biopharma and 5 mentions for Belite Bio. Xeris Biopharma's average media sentiment score of 0.64 beat Belite Bio's score of 0.20 indicating that Xeris Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Belite Bio 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Xeris Biopharma 7 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer XERS or AMRX?

In the previous week, Xeris Biopharma had 17 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 19 mentions for Xeris Biopharma and 2 mentions for Amneal Pharmaceuticals. Xeris Biopharma's average media sentiment score of 0.64 beat Amneal Pharmaceuticals' score of 0.51 indicating that Xeris Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xeris Biopharma 7 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amneal Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, LNTH or XERS?

Lantheus has higher revenue and earnings than Xeris Biopharma. Xeris Biopharma is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lantheus $1.54B 4.23 $233.56M $4.14 24.14 Xeris Biopharma $335.41M 4.94 $550K -$0.11 N/A

Is LNTH or XERS more profitable?

Lantheus has a net margin of 17.69% compared to Xeris Biopharma's net margin of -5.12%. Xeris Biopharma's return on equity of 338.21% beat Lantheus' return on equity. Company Net Margins Return on Equity Return on Assets Lantheus 17.69% 28.10% 14.35% Xeris Biopharma -5.12% 338.21% 3.50%

Does the media favor LNTH or XERS?

In the previous week, Xeris Biopharma had 9 more articles in the media than Lantheus. MarketBeat recorded 19 mentions for Xeris Biopharma and 10 mentions for Lantheus. Xeris Biopharma's average media sentiment score of 0.64 beat Lantheus' score of 0.23 indicating that Xeris Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 1 Very Positive mention(s) 0 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Xeris Biopharma 7 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, LQDA or XERS?

Xeris Biopharma has higher revenue and earnings than Liquidia. Xeris Biopharma is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Liquidia $158.32M 16.19 -$68.92M $1.37 20.91 Xeris Biopharma $335.41M 4.94 $550K -$0.11 N/A

Is LQDA or XERS more profitable?

Liquidia has a net margin of 30.74% compared to Xeris Biopharma's net margin of -5.12%. Xeris Biopharma's return on equity of 338.21% beat Liquidia's return on equity. Company Net Margins Return on Equity Return on Assets Liquidia 30.74% 149.65% 36.30% Xeris Biopharma -5.12% 338.21% 3.50%

Does the media refer more to LQDA or XERS?

In the previous week, Liquidia had 12 more articles in the media than Xeris Biopharma. MarketBeat recorded 31 mentions for Liquidia and 19 mentions for Xeris Biopharma. Xeris Biopharma's average media sentiment score of 0.64 beat Liquidia's score of 0.28 indicating that Xeris Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Liquidia 7 Very Positive mention(s) 6 Positive mention(s) 10 Neutral mention(s) 3 Negative mention(s) 2 Very Negative mention(s) Neutral Xeris Biopharma 7 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer XERS or DFTX?

In the previous week, Definium Therapeutics had 1 more articles in the media than Xeris Biopharma. MarketBeat recorded 20 mentions for Definium Therapeutics and 19 mentions for Xeris Biopharma. Xeris Biopharma's average media sentiment score of 0.64 beat Definium Therapeutics' score of 0.32 indicating that Xeris Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xeris Biopharma 7 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Definium Therapeutics 7 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Xeris Biopharma (XERS) Competitors

$9.08 -0.17 (-1.84%)

Closing price 04:00 PM Eastern

Extended Trading

$9.16 +0.08 (+0.94%)

As of 07:30 PM Eastern

Compare

XERS vs. BLTE, AMRX, LNTH, LQDA, and DFTX

Should you buy Xeris Biopharma stock or one of its competitors? Xeris Biopharma's main competitors and comparable companies include Belite Bio (BLTE), Amneal Pharmaceuticals (AMRX), Lantheus (LNTH), Liquidia (LQDA), and Definium Therapeutics (DFTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Xeris Biopharma compare to Belite Bio?

Belite Bio (NASDAQ:BLTE) and Xeris Biopharma (NASDAQ:XERS) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, media sentiment, institutional ownership and valuation.

In the previous week, Xeris Biopharma had 14 more articles in the media than Belite Bio. MarketBeat recorded 19 mentions for Xeris Biopharma and 5 mentions for Belite Bio. Xeris Biopharma's average media sentiment score of 0.64 beat Belite Bio's score of 0.20 indicating that Xeris Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Belite Bio	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Xeris Biopharma	7 Very Positive mention(s)	4 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Belite Bio presently has a consensus target price of $218.73, indicating a potential upside of 37.08%. Xeris Biopharma has a consensus target price of $12.80, indicating a potential upside of 40.97%. Given Xeris Biopharma's higher probable upside, analysts clearly believe Xeris Biopharma is more favorable than Belite Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Belite Bio	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Xeris Biopharma	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Xeris Biopharma has higher revenue and earnings than Belite Bio. Xeris Biopharma is trading at a lower price-to-earnings ratio than Belite Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Belite Bio	N/A	N/A	-$77.61M	-$2.73	N/A
Xeris Biopharma	$335.41M	4.94	$550K	-$0.11	N/A

0.5% of Belite Bio shares are held by institutional investors. Comparatively, 42.8% of Xeris Biopharma shares are held by institutional investors. 13.3% of Belite Bio shares are held by insiders. Comparatively, 4.4% of Xeris Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Belite Bio has a beta of -1.23, suggesting that its share price is 223% less volatile than the broader market. Comparatively, Xeris Biopharma has a beta of 0.53, suggesting that its share price is 47% less volatile than the broader market.

Belite Bio has a net margin of 0.00% compared to Xeris Biopharma's net margin of -5.12%. Xeris Biopharma's return on equity of 338.21% beat Belite Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Belite Bio	N/A	-11.84%	-11.62%
Xeris Biopharma	-5.12%	338.21%	3.50%

Summary

Xeris Biopharma beats Belite Bio on 10 of the 15 factors compared between the two stocks.

How does Xeris Biopharma compare to Amneal Pharmaceuticals?

Xeris Biopharma (NASDAQ:XERS) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings.

Xeris Biopharma has a beta of 0.53, indicating that its share price is 47% less volatile than the broader market. Comparatively, Amneal Pharmaceuticals has a beta of 1.22, indicating that its share price is 22% more volatile than the broader market.

In the previous week, Xeris Biopharma had 17 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 19 mentions for Xeris Biopharma and 2 mentions for Amneal Pharmaceuticals. Xeris Biopharma's average media sentiment score of 0.64 beat Amneal Pharmaceuticals' score of 0.51 indicating that Xeris Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xeris Biopharma	7 Very Positive mention(s)	4 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amneal Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

42.8% of Xeris Biopharma shares are held by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are held by institutional investors. 4.4% of Xeris Biopharma shares are held by insiders. Comparatively, 17.3% of Amneal Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Amneal Pharmaceuticals has a net margin of 5.05% compared to Xeris Biopharma's net margin of -5.12%. Xeris Biopharma's return on equity of 338.21% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xeris Biopharma	-5.12%	338.21%	3.50%
Amneal Pharmaceuticals	5.05%	-584.46%	7.78%

Amneal Pharmaceuticals has higher revenue and earnings than Xeris Biopharma. Xeris Biopharma is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xeris Biopharma	$335.41M	4.94	$550K	-$0.11	N/A
Amneal Pharmaceuticals	$3.02B	2.15	$72.06M	$0.49	41.43

Xeris Biopharma presently has a consensus price target of $12.80, indicating a potential upside of 40.97%. Amneal Pharmaceuticals has a consensus price target of $21.00, indicating a potential upside of 3.45%. Given Xeris Biopharma's higher probable upside, research analysts plainly believe Xeris Biopharma is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xeris Biopharma	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Amneal Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.90

Summary

Amneal Pharmaceuticals beats Xeris Biopharma on 10 of the 16 factors compared between the two stocks.

How does Xeris Biopharma compare to Lantheus?

Lantheus (NASDAQ:LNTH) and Xeris Biopharma (NASDAQ:XERS) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, earnings, valuation, risk, profitability and dividends.

In the previous week, Xeris Biopharma had 9 more articles in the media than Lantheus. MarketBeat recorded 19 mentions for Xeris Biopharma and 10 mentions for Lantheus. Xeris Biopharma's average media sentiment score of 0.64 beat Lantheus' score of 0.23 indicating that Xeris Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	1 Very Positive mention(s)	0 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Xeris Biopharma	7 Very Positive mention(s)	4 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.1% of Lantheus shares are held by institutional investors. Comparatively, 42.8% of Xeris Biopharma shares are held by institutional investors. 1.7% of Lantheus shares are held by company insiders. Comparatively, 4.4% of Xeris Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Lantheus has a net margin of 17.69% compared to Xeris Biopharma's net margin of -5.12%. Xeris Biopharma's return on equity of 338.21% beat Lantheus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	17.69%	28.10%	14.35%
Xeris Biopharma	-5.12%	338.21%	3.50%

Lantheus has a beta of -0.06, indicating that its stock price is 106% less volatile than the broader market. Comparatively, Xeris Biopharma has a beta of 0.53, indicating that its stock price is 47% less volatile than the broader market.

Lantheus currently has a consensus price target of $108.11, suggesting a potential upside of 8.15%. Xeris Biopharma has a consensus price target of $12.80, suggesting a potential upside of 40.97%. Given Xeris Biopharma's stronger consensus rating and higher probable upside, analysts clearly believe Xeris Biopharma is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.29
Xeris Biopharma	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Lantheus has higher revenue and earnings than Xeris Biopharma. Xeris Biopharma is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.54B	4.23	$233.56M	$4.14	24.14
Xeris Biopharma	$335.41M	4.94	$550K	-$0.11	N/A

Summary

Xeris Biopharma beats Lantheus on 8 of the 15 factors compared between the two stocks.

How does Xeris Biopharma compare to Liquidia?

Liquidia (NASDAQ:LQDA) and Xeris Biopharma (NASDAQ:XERS) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, media sentiment, analyst recommendations, profitability, risk, dividends and earnings.

Liquidia presently has a consensus price target of $83.69, indicating a potential upside of 192.22%. Xeris Biopharma has a consensus price target of $12.80, indicating a potential upside of 40.97%. Given Liquidia's higher probable upside, research analysts clearly believe Liquidia is more favorable than Xeris Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liquidia	2 Sell rating(s)	6 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.25
Xeris Biopharma	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

64.5% of Liquidia shares are owned by institutional investors. Comparatively, 42.8% of Xeris Biopharma shares are owned by institutional investors. 25.6% of Liquidia shares are owned by company insiders. Comparatively, 4.4% of Xeris Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Liquidia had 12 more articles in the media than Xeris Biopharma. MarketBeat recorded 31 mentions for Liquidia and 19 mentions for Xeris Biopharma. Xeris Biopharma's average media sentiment score of 0.64 beat Liquidia's score of 0.28 indicating that Xeris Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Liquidia	7 Very Positive mention(s)	6 Positive mention(s)	10 Neutral mention(s)	3 Negative mention(s)	2 Very Negative mention(s)	Neutral
Xeris Biopharma	7 Very Positive mention(s)	4 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Xeris Biopharma has higher revenue and earnings than Liquidia. Xeris Biopharma is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liquidia	$158.32M	16.19	-$68.92M	$1.37	20.91
Xeris Biopharma	$335.41M	4.94	$550K	-$0.11	N/A

Liquidia has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market. Comparatively, Xeris Biopharma has a beta of 0.53, meaning that its stock price is 47% less volatile than the broader market.

Liquidia has a net margin of 30.74% compared to Xeris Biopharma's net margin of -5.12%. Xeris Biopharma's return on equity of 338.21% beat Liquidia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liquidia	30.74%	149.65%	36.30%
Xeris Biopharma	-5.12%	338.21%	3.50%

Summary

Liquidia beats Xeris Biopharma on 11 of the 17 factors compared between the two stocks.

How does Xeris Biopharma compare to Definium Therapeutics?

Xeris Biopharma (NASDAQ:XERS) and Definium Therapeutics (NASDAQ:DFTX) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, earnings, dividends, risk, valuation and media sentiment.

Xeris Biopharma has higher revenue and earnings than Definium Therapeutics. Xeris Biopharma is trading at a lower price-to-earnings ratio than Definium Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xeris Biopharma	$335.41M	4.94	$550K	-$0.11	N/A
Definium Therapeutics	N/A	N/A	-$183.79M	-$3.43	N/A

In the previous week, Definium Therapeutics had 1 more articles in the media than Xeris Biopharma. MarketBeat recorded 20 mentions for Definium Therapeutics and 19 mentions for Xeris Biopharma. Xeris Biopharma's average media sentiment score of 0.64 beat Definium Therapeutics' score of 0.32 indicating that Xeris Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xeris Biopharma	7 Very Positive mention(s)	4 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Definium Therapeutics	7 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Xeris Biopharma has a beta of 0.53, meaning that its stock price is 47% less volatile than the broader market. Comparatively, Definium Therapeutics has a beta of 2.19, meaning that its stock price is 119% more volatile than the broader market.

Xeris Biopharma currently has a consensus target price of $12.80, suggesting a potential upside of 40.97%. Definium Therapeutics has a consensus target price of $64.88, suggesting a potential upside of 73.46%. Given Definium Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Definium Therapeutics is more favorable than Xeris Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xeris Biopharma	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	3.00

42.8% of Xeris Biopharma shares are owned by institutional investors. Comparatively, 27.9% of Definium Therapeutics shares are owned by institutional investors. 4.4% of Xeris Biopharma shares are owned by company insiders. Comparatively, 2.4% of Definium Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Definium Therapeutics has a net margin of 0.00% compared to Xeris Biopharma's net margin of -5.12%. Xeris Biopharma's return on equity of 338.21% beat Definium Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xeris Biopharma	-5.12%	338.21%	3.50%
Definium Therapeutics	N/A	-84.01%	-63.66%

Summary

Xeris Biopharma and Definium Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

Get Xeris Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XERS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XERS vs. The Competition

Export

Metric	Xeris Biopharma	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.69B	$12.27B	$7.14B	$13.10B
Dividend Yield	N/A	2.64%	2.54%	16.77%
P/E Ratio	-82.55	794.62	273.67	26.04
Price / Sales	5.67	757.46	612.51	90.64
Price / Cash	92.35	82.26	77.60	51.75
Price / Book	113.50	10.46	10.92	6.30
Net Income	$550K	$2.83B	$3.50B	$361.43M
7 Day Performance	-0.22%	-1.65%	-2.11%	-1.67%
1 Month Performance	5.83%	-5.77%	-6.34%	-3.94%
1 Year Performance	9.27%	-3.80%	8.81%	2.77%

Xeris Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XERS Xeris Biopharma	3.7827 of 5 stars	$9.08 -1.8%	$12.80 +41.0%	+15.5%	$1.69B	$335.41M	N/A	435	News Coverage Insider Trade
BLTE Belite Bio	3.3175 of 5 stars	$167.58 +1.0%	$218.73 +30.5%	+121.7%	$6.75B	N/A	N/A	41
AMRX Amneal Pharmaceuticals	3.1145 of 5 stars	$20.69 +0.9%	$21.00 +1.5%	+93.4%	$6.63B	$3.02B	42.35	8,500	Analyst Forecast
LNTH Lantheus	3.2165 of 5 stars	$99.60 -0.1%	$108.11 +8.5%	+93.0%	$6.52B	$1.54B	24.12	1,193	Positive News
LQDA Liquidia	4.1057 of 5 stars	$72.23 -2.0%	$98.08 +35.8%	+26.9%	$6.50B	$158.32M	53.02	216	Trending News Analyst Forecast Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XERS) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Xeris Biopharma (XERS) Competitors

XERS vs. BLTE, AMRX, LNTH, LQDA, and DFTX

How does Xeris Biopharma compare to Belite Bio?

Summary

How does Xeris Biopharma compare to Amneal Pharmaceuticals?

Summary

How does Xeris Biopharma compare to Lantheus?

Summary

How does Xeris Biopharma compare to Liquidia?

Summary

How does Xeris Biopharma compare to Definium Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XERS vs. The Competition

Xeris Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Xeris Biopharma (XERS) Competitors

XERS vs. BLTE, AMRX, LNTH, LQDA, and DFTX

How does Xeris Biopharma compare to Belite Bio?

Does the media prefer BLTE or XERS?

Do analysts prefer BLTE or XERS?

Which has better earnings and valuation, BLTE or XERS?

Do institutionals and insiders believe in BLTE or XERS?

Which has more risk & volatility, BLTE or XERS?

Is BLTE or XERS more profitable?

Summary

How does Xeris Biopharma compare to Amneal Pharmaceuticals?

Which has more volatility & risk, XERS or AMRX?

Does the media prefer XERS or AMRX?

Do institutionals and insiders have more ownership in XERS or AMRX?

Is XERS or AMRX more profitable?

Which has stronger earnings & valuation, XERS or AMRX?

Do analysts prefer XERS or AMRX?

Summary

How does Xeris Biopharma compare to Lantheus?

Does the media favor LNTH or XERS?

Do institutionals & insiders believe in LNTH or XERS?

Is LNTH or XERS more profitable?

Which has more volatility & risk, LNTH or XERS?

Do analysts rate LNTH or XERS?

Which has higher earnings and valuation, LNTH or XERS?

Summary

How does Xeris Biopharma compare to Liquidia?

Do analysts prefer LQDA or XERS?

Do insiders and institutionals believe in LQDA or XERS?

Does the media refer more to LQDA or XERS?

Which has better earnings and valuation, LQDA or XERS?

Which has more volatility & risk, LQDA or XERS?

Is LQDA or XERS more profitable?

Summary

How does Xeris Biopharma compare to Definium Therapeutics?

Which has stronger earnings & valuation, XERS or DFTX?

Does the media prefer XERS or DFTX?

Which has more volatility & risk, XERS or DFTX?

Do analysts recommend XERS or DFTX?

Do insiders & institutionals hold more shares of XERS or DFTX?

Is XERS or DFTX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XERS vs. The Competition

Xeris Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools